Any grade pneumonitis due to anti‐PD‐1/PD‐L1‐directed therapies has been estimated to occur in 4% of NSCLC patients, with higher‐grade pneumonitis estimated to occur in < 2% of patients.21, 22. The gene discussed is CD274; the disease is pneumonitis.